HER2 (encoded by ERBB2) is an oncogenic driver frequently altered in multiple cancer types, including breast cancer and malignancies of the gastrointestinal tract,1 where HER2-targeted therapies have improved patient outcomes and have received regulatory approvals. This evidence concerns the gene ERBB2 and cancer.